Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;15(1):92-98.
doi: 10.5114/aoms.2017.66160. Epub 2017 Jul 31.

Oxidative stress markers in patients with hereditary angioedema

Stefano R Del Giacco  1 , Davide Firinu  1 , Paola Lucia Minciullo  2 , Maria Pina Barca  1 , Paolo Emilio Manconi  1 , Gennaro Tartarisco  3 , Mariateresa Cristani  4 , Antonella Saija  4 , Sebastiano Gangemi  2
Affiliations

Oxidative stress markers in patients with hereditary angioedema

Stefano R Del Giacco et al. Arch Med Sci. 2019 Jan.

Abstract

Introduction: Hereditary angioedema due to C1-INH deficiency (C1-INH-HAE) or with normal C1-INH is characterized by recurrent swellings due to uncontrolled production of vasoactive mediators, among which bradykinin (BK) is crucial. Through the binding and activation of the two human BK-receptors, kinins may have dual beneficial and deleterious effects in vascular and inflammation physiopathology by inducing oxidative stress. We aimed to assess the serum concentrations of advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) in patients affected by HAE.

Material and methods: Blood samples were collected to measure the serum concentrations of AGEs and AOPPs by spectrofluorimetric and spectrophotometric methods in patients affected by C1-INH-HAE and FXII-HAE during the remission state.

Results: We showed that the circulating levels of AOPPs observed on control group (0.94 (0.36) nmol/mg) were significantly lower than those observed on the C1-INH-HAE group (1.68 (0.47) nmol/mg; p = 0.002) and FXII-HAE (1.50 (0.27) nmol/mg; p = 0.001). Moreover, the circulating levels of AGEs were significantly higher in C1-INH-HAE group (211.58 (151.05) AU/g; p = 0.02) than the FXII group (141.48 (89.59) AU/g), thus demonstrating a state of heightened oxidative stress.

Conclusions: Our observations show additional underlying events involved in HAE and are of central importance for further investigations of differences in bradykinin receptors signaling among the two disease subgroups.

Keywords: C1-inhibitor; bradykinin; hereditary angioedema; kinin; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The AOPP (nmol/mg protein) concentration among HAE patients and healthy controls. Box plot illustrates median (IQR) AOPP levels in groups of individuals of different HAE classes (C1, FXII) and control group. The Mann-Whitney U test was used for paired comparisons; p-values and medians are indicated in the figure
Figure 2
Figure 2
The AGE (AU/g protein) concentration among HAE patients and healthy controls. Box plot illustrates median (IQR) AGE levels in groups of individuals of different HAE classes (C1, FXII) and control group. The Bonferroni post hoc test was used for paired comparisons; p-values and medians are indicated in the figure
See this image and copyright information in PMC

References

    1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602–16. - PubMed
    1. Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy. 2015;70:1004–12. - PubMed
    1. Firinu D, Barca MP, Serusi L, et al. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report. Int J Immunopathol Pharmacol. 2012;25:269–73. - PubMed
    1. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–7. - PubMed
    1. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311–7. - PubMed